{"denoms":[{"counts":[{"groupId":"BG000","value":"373"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"557"}],"units":"Participants"}],"groups":[{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy were randomized to receive an intravenous infusion of DS8201a (initial dose of 5.4 mg/kg) over approximately 90 minutes. If there was no infusion-related reaction (IRR), T-DXd doses after the initial dose of 5.4 mg/kg were infused over a minimum of 30 minutes.","id":"BG000","title":"Trastuzumab Deruxtecan (T-DXd)"},{"description":"Participants with HER2-low, unresectable, and/or metastatic breast cancer who were previously treated with chemotherapy and randomized to a physician's choice (capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel) in which the dose, regimen, administration, and dose modification followed the label approved in the country of drug administration or the National Comprehensive Cancer Network guidelines.","id":"BG001","title":"Physician's Choice"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"290"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"426"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"131"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.6","value":"56.5"},{"groupId":"BG001","spread":"11.5","value":"56.5"},{"groupId":"BG002","spread":"10.9","value":"56.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"371"},{"groupId":"BG001","value":"184"},{"groupId":"BG002","value":"555"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"176"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"267"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"10"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"151"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"223"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Native Hawaiian or other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"55"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Missing"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Baseline characteristics were assessed in the Full Analysis Set. The Full Analysis Set included all participants randomized into the study, including those who did not receive a dose of study treatment. Participants were analyzed according to the treatments and strata assigned at randomization."}